# Claims

> Grounding: abstract-only. Claims are qualitative because the provided abstract reports no exact treatment-effect sizes, adverse-event rates, trial populations, or staging thresholds. The only year in claim statements is grounded from the title/metadata.

## C01: Anti-amyloid immunotherapy slows cognitive decline in early-stage Alzheimer's disease
- **Statement**: In the 2025 treatment paradigm described by the review, anti-amyloid immunotherapy with FDA-approved monoclonal antibodies such as lecanemab and donanemab has proven efficacy in slowing cognitive decline in early-stage Alzheimer's disease.
- **Status**: supported (per abstract; quantitative efficacy not available from provided input)
- **Falsification criteria**: The cited anti-amyloid monoclonal antibodies do not slow cognitive decline relative to appropriate controls in early-stage Alzheimer's disease, or are not FDA-approved as described.
- **Proof**: [E01]
- **Evidence basis**: The abstract directly states the approval examples and the efficacy direction.
- **Interpretation**: Disease-modifying therapy shifts management toward early biological diagnosis and intervention.
- **Dependencies**: none
- **Sources**:
  - 2025 <- metadata.md (Year) «**Year**: 2025  (2025-05-30)» [input]
  - "lecanemab and donanemab" <- metadata.md (Abstract) «including the US Food & Drug Administration (FDA)-approved monoclonal antibodies such as lecanemab and donanemab» [input]
  - "slowing cognitive decline in early-stage AD" <- metadata.md (Abstract) «has proven efficacy in slowing cognitive decline in early-stage AD» [result]
- **Tags**: anti-amyloid immunotherapy, lecanemab, donanemab, early-stage Alzheimer's disease

## C02: Cholinesterase inhibitors and memantine remain standard symptomatic treatments
- **Statement**: Cholinesterase inhibitors and memantine remain standard treatments for mild, moderate to severe dementia, providing symptomatic relief and functional stabilization.
- **Status**: supported (per abstract)
- **Falsification criteria**: These treatments are no longer standard treatments for the stated dementia severities, or they fail to provide symptomatic relief or functional stabilization in the reviewed treatment paradigm.
- **Proof**: [E02]
- **Evidence basis**: The abstract directly states the standard-treatment role and intended symptomatic/functional effects.
- **Interpretation**: Established symptomatic care remains relevant alongside disease-modifying therapy.
- **Dependencies**: none
- **Sources**:
  - "Cholinesterase inhibitors and memantine" <- metadata.md (Abstract) «Cholinesterase inhibitors and memantine remain the standard treatments for mild, moderate to severe dementia» [input]
  - "symptomatic relief and functional stabilization" <- metadata.md (Abstract) «providing symptomatic relief and functional stabilization» [result]
- **Tags**: cholinesterase inhibitors, memantine, symptomatic therapy, dementia

## C03: Biomarker-based diagnostic frameworks enable individualized treatment planning
- **Statement**: An updated diagnostic framework incorporating fluid and imaging biomarkers enables more precise staging and individualized treatment plans for Alzheimer's disease.
- **Status**: supported (per abstract)
- **Falsification criteria**: Fluid and imaging biomarkers do not improve staging precision or do not inform individualized treatment planning.
- **Proof**: [E03]
- **Evidence basis**: The abstract directly states that the updated diagnostic framework enables more precise staging and individualized plans.
- **Interpretation**: Biomarker diagnostics are a coordinating layer for assigning therapies across the disease spectrum.
- **Dependencies**: C01
- **Sources**:
  - "fluid and imaging biomarkers" <- metadata.md (Abstract) «incorporating fluid and imaging biomarkers» [input]
  - "more precise staging and individualized treatment plans" <- metadata.md (Abstract) «enables more precise staging and individualized treatment plans» [result]
- **Tags**: biomarkers, staging, fluid biomarkers, imaging biomarkers, individualized treatment

## C04: Personalized multimodal care is part of the updated treatment approach
- **Statement**: The review highlights personalized multimodal treatment approaches that integrate lifestyle modifications, cognitive training, and caregiver support.
- **Status**: supported (per abstract)
- **Falsification criteria**: The review does not recommend or highlight integration of lifestyle modification, cognitive training, and caregiver support as part of treatment planning.
- **Proof**: [E04]
- **Evidence basis**: The abstract directly lists the non-pharmacological components.
- **Interpretation**: Alzheimer's disease care is framed as a combined pharmacological and non-pharmacological program.
- **Dependencies**: C02, C03
- **Sources**:
  - "personalized, multimodal treatment approaches" <- metadata.md (Abstract) «this review highlights the importance of personalized, multimodal treatment approaches» [input]
  - "lifestyle modifications, cognitive training, and caregiver support" <- metadata.md (Abstract) «integrate lifestyle modifications, cognitive training, and caregiver support» [input]
- **Tags**: multimodal care, lifestyle modification, cognitive training, caregiver support

## C05: Current treatment strategy remains constrained by selection, side effects, access, and evidence maturation
- **Statement**: Despite treatment advances, the abstract identifies unresolved challenges in patient selection, treatment-related side effects, accessibility to appropriate therapies, and further refinement through ongoing clinical trials and real-world evidence.
- **Status**: supported (per abstract)
- **Falsification criteria**: The review does not identify these challenges, or later evidence resolves them such that they no longer constrain treatment strategy.
- **Proof**: [E05]
- **Evidence basis**: The abstract directly lists these challenges and the need for further trial and real-world evidence.
- **Interpretation**: The treatment paradigm is actionable but not settled; implementation and safety constraints remain central.
- **Dependencies**: C01, C03, C04
- **Sources**:
  - "patient selection" <- metadata.md (Abstract) «challenges still lie in refining patient selection» [input]
  - "treatment-related side effects" <- metadata.md (Abstract) «addressing treatment-related side effects» [input]
  - "accessibility to appropriate therapies" <- metadata.md (Abstract) «ensuring accessibility to appropriate therapies» [input]
  - "ongoing clinical trials and real-world evidence" <- metadata.md (Abstract) «ongoing clinical trials and real-world evidence will further refine treatment strategies» [input]
- **Tags**: implementation, patient selection, side effects, access, real-world evidence
